GENMAB AS DKK1 (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm presently has a $177.00 price target on the stock. Zacks Investment Research’s target price suggests a potential upside of 11.85% from the company’s previous close.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. began coverage on shares of GENMAB AS DKK1 in a research report on Tuesday, June 21st. They set a “neutral” rating on the stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of GENMAB AS DKK1 (OTCMKTS:GNMSF) remained flat at $158.25 during midday trading on Tuesday. The company has a market cap of $9.47 billion, a PE ratio of 94.14 and a beta of 0.89. The stock’s 50-day moving average price is $172.39 and its 200 day moving average price is $158.34. GENMAB AS DKK1 has a 52 week low of $93.25 and a 52 week high of $183.00.

Receive News & Ratings for GENMAB AS DKK1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB AS DKK1 and related companies with's FREE daily email newsletter.